Cargando…
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864649/ https://www.ncbi.nlm.nih.gov/pubmed/34965297 http://dx.doi.org/10.1182/bloodadvances.2019001205 |
| _version_ | 1784655500911050752 |
|---|---|
| author | Seymour, John F. |
| author_facet | Seymour, John F. |
| author_sort | Seymour, John F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8864649 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88646492022-02-23 Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i Seymour, John F. Blood Adv Counterpoint American Society of Hematology 2022-02-22 /pmc/articles/PMC8864649/ /pubmed/34965297 http://dx.doi.org/10.1182/bloodadvances.2019001205 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Counterpoint Seymour, John F. Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i |
| title | Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i |
| title_full | Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i |
| title_fullStr | Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i |
| title_full_unstemmed | Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i |
| title_short | Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i |
| title_sort | is btki or bcl2i preferable as first novel therapy in patients with cll? the case for bcl2i |
| topic | Counterpoint |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864649/ https://www.ncbi.nlm.nih.gov/pubmed/34965297 http://dx.doi.org/10.1182/bloodadvances.2019001205 |
| work_keys_str_mv | AT seymourjohnf isbtkiorbcl2ipreferableasfirstnoveltherapyinpatientswithcllthecaseforbcl2i |